IDIA News - Candlesense

Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension

(IDIA) Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025 Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center...

What measurable milestones (e.g., patient enrollment, real‑world evidence generation, AI tool deployment) are tied to the three‑phase IMPACT‑HTN program, and how might they influence long‑term market share in the difficult‑to‑control hypertension segment? What is the expected timeline for regulatory approval and commercial rollout of TRYVIO™ (aprocitentan) in the U.S., and how does it compare to competing hypertension therapies? How will the collaboration with Stanford and Duke and the launch of IMPACT-HTN affect Idorsia's near‑term revenue outlook and stock valuation?

Collaboration

1 day ago

Read more globenewswire

Idorsia furthers the science of sleep and insomnia at World Sleep 2025

(IDIA) Allschwil, Switzerland – September 1, 2025 Idorsia Ltd (SIX: IDIA) continues its commitment to furthering the science of sleep and insomnia with a symposium and eight poster presentations at...

Research

5 days ago

Read more globenewswire

Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension

Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the e...

What pricing, reimbursement, and margin assumptions are being used for TRYVIO™, and how could they affect the company’s long‑term cash‑flow outlook? What market share can TRYVIO™ realistically capture versus existing antihypertensive classes such as ACE inhibitors, ARBs, and calcium‑channel blockers? How will the FDA approval of TRYVIO™ impact Idorsia’s revenue forecasts and stock valuation?

Fda approval

9 days ago

Read more globenewswire

TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension

Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025 Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included...

What are the expected volume and revenue growth trajectories for TRYVIO™ given its new guideline endorsement? What potential market share could TRYVIO™ capture from existing hypertension therapies and competitors? How will the inclusion of TRYVIO™ in the ACC/AHA guidelines affect Idorsia Ltd's share price in the short term?

Guidelines

18 days ago

Read more globenewswire

TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”

Allschwil, Switzerland – August 12, 2025 Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has no...

What historical data exists on previous Prix Galien nominees and winners and their subsequent stock performance? How might the nomination impact Idorsia's partnership or licensing opportunities with larger pharma companies? Is there any risk that the nomination could raise expectations that, if unmet, might lead to a negative price reaction?

Awards

25 days ago

Read more globenewswire

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR

How might the market's perception of Idorsia's growth prospects change following this announcement? What are the tax implications of the bond repurchase for both the company and bondholders? Could the repurchase lead to a re-rating of Idorsia's stock by analysts or a shift in target price?

Finance

26 days ago

Read more globenewswire